Acorda Therapeutics Inc ACOR shares are trading higher by $1.83 (6.7 percent) at $30.13 in Thursday's session.
At 2:47 p.m. ET, it was trading at the $27.50 area, when the news that the company had a favorable patent ruling related to Ampyra. That instigated a straight up move to $30.40 before it was halted on a circuit breaker. Coming out of the halt, it added another $3.00 before finally peaking at $33.00 in the first minute after the trading halt was lifted.
That marks the highest level for Acorda's stock in nearly a year, as it peaked on March 11, 2016 at $36.18. Only four days later, it closed at $25.61 when the company was on the other end of a patent ruling vs. Alkem Laboratories.
Since reaching that elevated level, it's now below the level prior to the trading halt. If the issue can close above $30.00, it will be the first time since March 11, 2016, when it ended that session at $32.00.
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.